MIAMI, July 07 10, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cell therapies for chronic, aging-related, and life-threatening diseases, today announced a summary regarding Lomecel- B Phase 2a trial in Alzheimer’s disease (AD) has been accepted for poster presentation at the Alzheimer’s Association International Conference (AAIC), to be held July 31-August 4, 2022 in San Diego , in California, as well as virtually.
“We are pleased that AAIC, the premier organization in AD, has accepted our poster outlining the design of Longeveron’s second study in Alzheimer’s disease. Recruitment is currently underway for the Phase 2a trial, and we are excited about the potential of Lomecel-B as a treatment for this significant unmet medical need,” said Chris Min, MD, Ph.D. Acting CEO and Medical Director. Officer.
Earlier this year, Longeveron published a peer-reviewed review of its Phase 1b trial in Alzheimer’s disease in Alzheimer’s and dementia® showing that the trial met its primary endpoint, demonstrating that Lomecel-B was well tolerated in this patient population.
The details of the poster that will be presented at AAIC 2022 are as follows:
Title: The effects of multiple doses of Lomecel-B, Longeveron’s cell therapy, on Alzheimer’s disease: study design and rationale for this multicenter phase 2a clinical trial.
Format: Poster presentation
Attach #: 67168
Authors: Kevin N. Ramdas, MD, MPH, Mark Brody, MD, Brad Herskowitz, MD, Marc Agronin, MD, Jorge G. Ruiz, MD, Ana Fuquay, Savannah Rodriguez, Danial Mehranfard, Pharm.D., MBA, Lisa McClain- Moss, Dan Gincel, Ph.D., Joshua M. Hare, MD, and Anthony A. Oliva Jr., PhD
Date: Tuesday, August 2, 2022
Time: 12:30 p.m.
Information about the annual AAIC is available at https://aaic.alz.org/.
About Longeveron Inc.
Longeveron is a clinical-stage biotechnology company developing cell therapies for specific life-threatening, age-related conditions. The Company’s lead investigational product is the cell therapy product Lomecel-B™, which is derived from culture-grown medicinal signaling cells (MSCs) that come from the bone marrow of healthy young adult donors. Longeveron believes that by using the same cells that support tissue repair, organ maintenance and immune system function, it can develop safe and effective therapies for some of the most challenging disorders associated with the aging process and other medical conditions. Longeveron is currently sponsoring phase 1 and 2 clinical trials in the following indications: Alzheimer’s disease, hypoplastic left heart syndrome (HLHS), frailty associated with aging and acute respiratory distress syndrome (ARDS). Additional information about the Company is available at www.longeveron.com.
Stern IR, Inc.